drugset / Trial / NCT07295496
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)
Timeline
- Start
- 2025-12-08
- Primary completion
- 2026-06-07
- Completion
- 2026-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IBI3011 | Monoclonal antibody | 300 mg | — |